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Neutrophil granulocytes play an important role in the early stages of microbial 
infection. The neutrophils have to leave the blood stream and migrate out into the 
tissue where they phagocytose microbes and cell debris from damaged host tissues. 
Their antimicrobial substances might also contribute to the tissue injury commonly 
associated with inflammation. Migration to the inflammatory site is directed by 
chemoattractants, which guide and activate neutrophils via specific receptors. One 
important class of receptors is the group of formyl peptide receptors (FPRs) of which 
two members are expressed on human neutrophils, FPR and FPR-like 1 (FPRL1). 
These receptors display large sequence homologies and belong to a larger family of G-
protein-coupled receptors. FPR recognizes formylated peptides generated during 
bacterial growth and can thus be viewed as a "pattern recognition receptor", while 
FPRL1 was until recently an orphan receptor with unknown functions and agonists. 
A cecropin-like antibacterial peptide from the gastric pathogen Helicobacter pylori, 
Hp(2-20), was found to be a complete neutrophil activator that mediates Chemotaxis, 
induces granule mobilization and activates the NADPH-oxidase to release oxygen free 
radicals. The receptor utilized by Hp(2-20) was identified as FPRL1. This receptor has 
in the last years been shown to recognize a large number of peptides/proteins, many of 
which represent cleavage products of full-length proteins in themselves unable to 
activate the receptor. Thus, also FPRL1 could be considered a "pattern recognition 
receptor" activated indirectly by the proteolytic cascades accompanying tissue 
damage. The Hp(2-20)-induced activity was increased when neutrophil storage-
organelles were mobilized to the plasma membrane by incubation with bacterial 
lipopolysaccharide (LPS). A large pool of FPRL1 was found in the easily mobilized 
gelatinase granules, implying that the enhanced response was due to receptor 
upregulation by granule mobilization. Also murine neutrophils responded to 
FPR/FPRL1 agonists, an activation partly subjected to the same regulatory events as 
human neutrophils. However, important differences between cells from the two 
species were also found. Neutrophils from mice and men differ not only in relative 
abundance, but also in receptor arsenals, suggesting that humans and mice have 
developed distinct sensitivities towards different agonists due to co-evolution with 
different pathogens. 
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Abbreviations 
AD Alzheimer's disease 
DAG diacylglycerol 
fMLF A-formyl-methionyl-leucyl-phenylalanine 
FPR formyl peptide receptor 
FPRL1 formyl peptide receptor-like 1 
FPRL2 formyl peptide receptor-like 2 
GPCR G-protein-coupled receptor 
HBP heparin binding protein 
hCAP18 human cationic antimicrobial protein, 18 kD 
Hp-NAP Helicobacter pylori neutrophil activating protein 
IPs inositol 1,4,5-trisphosphate 
LJP localized juvenile periodontitis 
LPS lipopolysaccharide 
LXA4 lipoxin A4 
MPO myeloperoxidase 
PAF platelet activating factor 
PAMP pathogen-associated molecular pattern 
PI3K phosphoinositide 3-kinase 
PIP2 phosphatidylinositol 4, 5-bisphosphate 
PIP3 phosphatidylinositol 3, 4, 5-trisphosphate 
PKC protein kinase C 
PLC phospholipase C 
ROS reactive oxygen species 
SAA serum amyloid A 
TLR Toll-like receptor 
TNF a tumor necrosis factor a 
uPAR urokinase-type plasminogen activator receptor 
1. Introduction 
1. Introduction 
The neutrophils are the most abundant cells among the human blood 
leukocytes and play an important role in combating the early stages of 
infection as well as disposing of cell debris upon tissue damage. For these 
purposes the neutrophils have to leave the circulation and migrate out into the 
tissue where they phagocytose microbes and release their impressive arsenal 
of antimicrobial substances and degradative enzymes. A proper and tightly 
controlled regulation of the release of these substances are of utmost 
importance and failure to do so may cause serious tissue damage and result in 
a variety of inflammatory disease states. As part of the innate immune 
defense the neutrophils are, in contrast to the cells of the adaptive immune 
system, not dependent on gradual maturation of specific recognition, but 
instead rely on preformed, germ-line encoded, receptor structures. These 
receptors can recognize infectious agents, directly or indirectly through 
opsonins, as well as a variety of "danger signals" calling for an inflammatory 
response. An important class of receptors responsible for this recognition in 
neutrophils is the group of formyl peptide receptors (FPRs). These are 
serpentine seven transmembrane spanning G-protein coupled structures 
belonging to the chemoattractant family of receptors and neutrophils express 
two different FPRs (out of the three human variants), namely FPR and F PR-
like 1 (FPRL1). The former receptor is known to recognize a variety of N-
formylated peptides generated during bacterial growth. The latter functions as 
a low affinity receptor for formylated peptides but has lately been shown to 
recognize a number of seemingly unrelated peptides/proteins/lipids and has 
thus come to be regarded as a promiscuous receptor. This review will mainly 
focus on FPRL1 in terms of regulation, effector functions affected by its 
activation, possible involvement in different clinical settings and whether the 
promiscuous feature of FPRL1 can be regarded as a concept of pattern 
recognition and a way of reacting to seemingly unspecific danger signals. 
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2. Leukocyte functions induced by 
chemoattractants 
The recruitment of neutrophils to sites of infection or inflammation is a rapid 
process dependent on directed cellular migration, a process known as 
Chemotaxis. This migration occurs along a gradient of chemical mediators, 
chemoattractants, of both exogenous and endogenous origin. 
Chemoattractants include bacterial products, products of the complement 
cascade (e.g., C5a), a variety of cytokines known as chemokines and some 
secreted lipids derived from phospholipid metabolism (i.e., platelet activating 
factor (PAF) and leukotriene B4). These substances can induce additional 
responses in neutrophils apart from guiding their migration to an 
inflammatory focus, including granule mobilization and activation of the 
NADPH-oxidase. Chemoattractants are thus involved at several stages in the 
mission of a neutrophil and gradually alters it from being a resting cell that 
circulates the blood stream into becoming an actively cytotoxic cell in the 
inflamed tissue. 
2.1 Chemotaxis 
The directed migration of a neutrophil is a highly complex process, 
depending not only on actin dynamics but also to a high degree on integrin-
mediated adhesion. When a neutrophil is exposed to a biochemical gradient 
of a chemoattractant, the cell adopts a polarized morphology with a leading 
edge pointed towards the highest concentration of chemoattractant. A highly 
controlled actin equilibrium featuring polymerization in the leading edge and 
depolymerisation in the trailing edge keeps the cell in motion (20). In vivo, 
the directed migration of neutrophils to an inflammatory focus is an even 
more complicated process involving a constant interplay between the 
migrating neutrophil and the surrounding cells and tissues in addition to 
various endogenous molecules affecting the state of the neutrophil. An 
example of this intricate interplay is diapedesis, the process where the 
neutrophils pass the endothelial cell layer of the blood vessels and move into 
the surrounding tissue. Activation of the endothelial cells is required for the 
initial communication with circulating neutrophils. Upon stimulation with 
e.g., cytokines or complement factors the endothelial cells rapidly upregulate 
their surface expression of P-selectin (12) that recognizes carbohydrates 
present on the surface of resting neutrophils (79). This is a transient 
interaction of low affinity and causes the neutrophils to slow down and roll 
along the endothelium. The next step involves activation of the neutrophils 
by low concentrations of chemoattractants of exogenous or endogenous 
origin, e.g., IL-8 or PAF produced by activated endothelial cells (98). This 
results in activation of the neutrophils' surface-localized integrins that bind to 
extracellular matrix proteins and mediate a high affinity interaction and thus 
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a more firm attachment between the neutrophils and the endothelial cells. 
Ligation of the integrins also induces a signal transduction cascade in the 
neutrophils leading to their spread along the endothelium and altered 
sensitivity to other stimuli (10, 87). Neutrophils with occupied integrins can 
then be stimulated to release heparin-binding protein (HBP) that binds to an 
as yet unidentified receptor present on the endothelial cells. The binding of 
HBP induces mobilization of intracellular calcium as well as the formation of 
actin-stress fibers spanning the endothelial cells. These events lead to an 
increase in endothelial monolayer permeability indicating that HBP released 
from activated neutrophils actively induces endothelial cells to contract and 
permit the passage of the neutrophils (44). When the neutrophils have passed 
the barrier consisting of the blood vessel endothelium, they begin to migrate 
along the chemotactic gradient toward the inflammatory focus. 
2.2 Granule mobilization 
Mature neutrophils show very low levels of de novo protein synthesis. 
Instead they rely on the function of preformed proteins stored in a variety of 
intracellular storage organelles called granules (16). The granules are 
membrane enclosed vesicles formed during maturation of the neutrophils in 
the bone marrow and contain both soluble matrix proteins and membrane-
associated molecules. In addition, storage organelles called secretory vesicles 
are formed by endocytosis of the plasma membrane during the late stages of 
neutrophil maturation. With respect to orientation, the granule membrane is 
organized in an "inverted" fashion in order to obtain the correct functional 
direction of membrane-associated molecules (e.g., receptors) upon fusion of 
the granule membrane with the plasma membrane. The mobilization of 
granules, degranulation/secretion/exocytosis, is an important process starting 
upon neutrophil attachment to the endothelium, continuing during diapedesis 
and Chemotaxis and ending at the inflammatory site with release 
(extracellular or phagosomal) of microbicidal substances. 
To date, four different granule subsets have been identified and classified 
according to content of matrix and membrane proteins and the propensity to 
undergo exocytosis and there appears to be a logical correlation between the 
content of the granules and the order in which they are mobilized. The most 
easily mobilized organelles are the secretory vesicles that upon exocytosis 
secrete plasma proteins and supply the plasma membrane with chemotactic-
and adhesion- receptors, the latter promoting the interaction with the 
endothelial cells. The gelatinase granules are the next organelles to become 
mobilized, supplying the plasma membrane with more chemotactic receptors 
and releasing matrix-degrading enzymes to facilitate diapedesis and 
Chemotaxis. Even more stimulation is required for the specific granules to be 
mobilized. These granules contain phagocytic receptors and some 
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antimicrobial substances. However, the major part of the microbicidal 
substances is present in the azurophil granules that also contain a variety of 
lysosomal enzymes. The azurophil granules are delivered to the engulfed 
prey by phagolysosomal fusion and are not secreted extracellularly (15). 
As outlined above, some granules need very little stimulation, such as a very 
low dose of a chemoattractant, in order to become mobilized to the cell 
surface. Other granules require higher doses of chemoattractant to undergo 
exocytosis. Apart from chemoattractants, other proinflammatory substances 
without chemotactic activity can also mediate degranulation e.g., tumor 
necrosis factor a (TNF-a) (41) and bacterial lipopolysaccharide (LPS) (Paper 
III). In line with the fact that a low dose of chemoattractant stimulates 
exocytosis of fewer granule types than does a higher dose, the difference in 
propensity to undergo exocytosis between the different granule types has 
been correlated with levels of cytosolic calcium (69, 89). Whether signal 
transduction mechanisms could explain also the relative difference in 
secretory potency between different chemoattractants remains to be 
established. 
It is also worth to mention that the classification of the neutrophil granules is 
not definite and with all probability there exists granules that do not fit the 
current scheme and it seems logical to assume that the distinctions between 
the granule subsets are not absolute. 
2.3 Activation of the NADPH-oxidase 
The microbicidal arsenal of the neutrophils can be divided in an oxygen-
independent branch, including antibacterial peptides/proteins and catalytic 
enzymes that are stored primarily in the azurophil granules (see above), and 
an oxygen-dependent branch. The oxygen-dependent substances comprise a 
variety of reactive oxygen species (ROS) formed as a result of NADPH-
oxidase activation. The NADPH-oxidase is a membrane-bound electron 
transport chain that ferries electrons from cytoplasmic NADPH to molecular 
oxygen on the opposite side of the membrane, resulting in the formation of 
highly reactive superoxide anion and hydrogen peroxide. These compounds 
can then be further processed, either by the product of nitric oxide synthase to 
form the very reactive peroxynitrite molecule, or by myeloperoxidase (MPO) 
(26). The MPO is localized in the azurophil granules of the neutrophils and 
catalyses the reaction of reduced oxygen species with halides forming 
hypohalous acid and subsequently other toxic halogenated compounds. 
The NADPH-oxidase is a complex enzyme system consisting of both 
membrane-bound subunits (gp91phox and p22phox) and cytosolic components 
(p40phox, p47phox and p67phox) and the proper assembly of these subunits into 
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an active enzyme is a highly regulated process (reviewed in (5, 25)). The 
neutrophils harbor two pools of NADPH-oxidase, one localized in the plasma 
membrane that upon activation releases ROS extracellularly, and one 
localized in granule membranes that generates intracellular ROS. Activation 
of the NADPH-oxidase in response to chemoattractants results in an 
extracellular release of ROS that does not only have deleterious effects on 
microbes, but may also inflict serious damage on surrounding tissues. The 
significance of the intracellularly generated ROS has not been clearly 
established, although they have been implicated as signaling molecules (47, 
117) regulating e.g., apoptotic processes (71). The localization of the ROS 
generation is determined by the nature of the activator (26) and the signal 
transduction events leading to an intracellular oxidative burst have been 
shown to, in part, differ from the events leading to an extracellular release of 
ROS (60). Interestingly, the ability of neutrophils to generate ROS 
intracellularly seems not to be a preserved feature between species, since 
murine neutrophils appear to be devoid of an activatable pool of intracellular 
NADPH-oxidase (Paper IV). 
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3. Chemotactic Receptors 
Comparing the various chemoattractant receptors that have been identified 
over the years reveals several important similarities in structure and function. 
Chemoattractant receptors belong to a group of G-protein coupled receptors 
(GPCRs) with a serpentine orientation in the plasma membrane, starting with 
an extracellular amino terminus followed by seven helical transmembrane 
domains and an intracellular carboxyl terminus. This family of receptors have 
structures and to varying degrees also signaling components that are common 
throughout the animal kingdom and implemented in a variety of biological 
contexts (78). For example, the receptors responsible for detecting odors in 
sensory neurons in man (33) as well as in lower eukaryotes, e.g., insects, are 
seven transmembrane spanning GPCRs (19, 112). It is interesting to note that 
the chemotactic receptors that are used to guide inflammatory cells are 
similar to those involved in the complex process of odor detection. Thus, it is 
perhaps not too farfetched to say that the neutrophils "smell" their way to an 
infected tissue. 
The carboxyl terminus of the chemoattractant receptors contains potential 
phosphorylation sites that function as regulatory elements in receptor 
internalization and termination of signaling. This part of the receptor has 
also, together with other cytoplasmic parts and transmembrane domains, been 
implicated in the interaction with the signal transducing G-protein (92, 107), 
while the extracellular parts and also certain transmembrane regions are 
involved in agonist binding (85, 90). 
One of the most studied chemoattractant receptors is the formyl peptide 
receptor (FPR) that enables neutrophils to "sniff' their way towards a 
bacterial infection. The fact that neutrophils are attracted by bacterial 
colonization and growth in the infected tissue has been known for a long time 
(54). The phenomenon gained a molecular explanation by the discovery that 
iV-formylated peptides can function as potent chemoattractants (106), while 
similar peptides lacking the formyl group were devoid of chemotactic 
activity. Since bacteria but not eukaryotic cells start their protein synthesis 
with a Ar-formylated methionine residue, A'-formylated peptides seem like 
logical molecules for the neutrophil to use as recognition pattern when 
responding to bacterial invasion. Later research has shown that A -formylated 
peptides are indeed a major contributing factor to the chemotactic potential of 
different bacterial species (77, 103). 
Soon after the initial observation that formylated peptides, in particular the 
prototypic peptide /V-fbrmyl-methionyl-leucyl-phenylalanine (fMLF), 
function as chemoattractants, the quest began to unravel the mechanism by 
which neutrophils react to these peptides. Gradually, it became clear that the 
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interaction between the formylated peptides and the neutrophil is a highly 
specific receptor-ligand interaction. The initial work to purify and 
characterize the potential receptor by biochemical means generated data 
showing that the receptor was glycosylated (32, 75, 88) and tightly associated 
with the plasma membrane (8). Furthermore, it was shown that treatment of 
guinea pig neutrophils with pertussis toxin inhibited functional responses 
mediated via the potential receptor, suggesting that G-proteins are involved 
in the signaling (14). Due to the tight association of FPR to the plasma 
membrane, attempts to purify the receptor were at large unsuccessful, but as 
outlined above, the receptor was already partially characterized when the 
high affinity receptor for formylated peptides, the human FPR, was first 
cloned by Boulay in 1990 (17). The results obtained during the cloning of 
FPR also implicated the existence of related receptor variants and later work 
has identified two additional FPR-related receptors, the FPRL1 (9, 86, 128) 
and FPRL2 (9). 
In humans, the expression patterns of the formyl peptide family of receptors 
(FPR, FPRL1 and FPRL2) differ between leukocytes. Neutrophils express 
FPR and FPRL1, while monocytes have been shown to express the complete 
set (34). Receptors of the FPR family have also been found in other cell 
types, e.g., dendritic cells, hepatocytes, microglial cells and astrocytes (66, 
94). Expression of FPRL1 has been reported in a variety of epithelial cell 
lines (48), although the functional consequences of this expression remain to 
be established. As described in Fig. 1, the degree of similarity between the 
human FPRs is relatively high, with the transmembrane domains and the 
cytosolic parts showing the highest conservation. The genes encoding the 
three receptor variants are all clustered on chromosome 19ql3.3 (86) 
suggesting that their differences have arisen by divergent evolution after 
relatively late duplication events. 
3.1 Exploring the FPRs, in vitro amd in vivo 
Most of the information regarding the FPRs, their regulation and specificities 
has evolved from in vitro experiments with varying degrees of complexity. 
Cloning and transfection of a particular receptor in an unrelated cell type that 
is not normally expressing the receptor, and stimulation with purified 
agonists represent the most clear-cut and less complex experimental set-ups. 
The use of transfected FPRs has enabled detailed analyses of affinities for 
different agonists and by mutating the receptor sequence, knowledge 
concerning more sophisticated receptor-associated processes has been gained. 
For example, the parts of FPR involved in agonist binding and G-protein 
coupling (85) was defined by this approach, as was the molecular 
requirements for FPR internalization (95). 
13 
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Although the use of transfected cell lines has undoubtedly generated large 
amounts of interesting data, this approach suffers from several important 
drawbacks when it comes to translating the results to the in vivo situation, 
such as the heterogeneity in expression levels and the fact that the transfected 
receptor may behave erratic when expressed outside of its normal habitat. To 
remedy the latter and add a level of complexity to the experimental system, 
purified agonists and purified cells (e.g., neutrophils) are often used. The 
variety of receptors expressed to different extents by the neutrophil better 
represents the proper background on which to test the effects of an agonist. In 
order to further complicate the set-up, non-purified agonists obtained from 
their natural habitats (such as bacterial extracts) can be used on a mixture of 
cells aimed to mimic an inflammatory infiltrate. 
The experimental system most employed to ensure a maximal level of 
complexity and resemblance of human inflammatory processes are animal 
models. Various animal models have enabled a much-increased 
understanding of various aspects of inflammation and neutrophil physiology, 
not least due to the possibility of performing genetic manipulations in a 
controlled genetic background to investigate the importance of a particular 
gene. This approach was used by Murphy and co-workers to investigate the 
role of the murine FPR homologue in an infectious model. Neutrophils from 
the mutant mice were shown to be defect in Chemotaxis against fMLF and 
mice lacking this receptor were found to be more susceptible to Listeria 
monocytogenes infection and were defect in bacterial clearance, implying an 
important role for FPR in vivo (43). In animal models other than murine, 
investigators have reported varying degrees of affinity for formylated 
peptides and varying sequence homologies of the responsible receptor. The 
rabbit FPR, for example, is 78% identical to its human counterpart and shows 
very similar binding properties (129). On the other hand, porcine neutrophils 
have been shown to be totally unresponsive to fMLF (35) and neutrophils 
from horse have been shown to respond functionally to fMLF by granule 
mobilization, but are inert with regards to Chemotaxis (110). These data 
imply that the responsiveness to formylated peptides is not a trait of high 
inter-species conservation. 
Even though there are a number of ways to make an in vitro system more in 
v/vo-like one has to be aware that the events taking place in a test tube always 
represent much-simplified versions of extremely complex processes taking 
place in the human body. For instance, a very complex mixture of pro- and 
anti-inflammatory substances acting in concert influences the inflammatory 
process, and the combined effect of a mixture of agonists is not always 
merely the sum of the individual effects induced by the agonists (discussed in 
Paper I). Furthermore, an agonist that exerts activating effects on one 
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particular cell type may well have (secondary) inhibiting effects on other 
cells (11). 
Despite all drawbacks in employing over-simplified in vitro systems and 
even various in vivo models, studies using highly purified agonists in single 
receptor systems are often necessary to enable proper interpretation of data 
generated from more complex settings, and the combined knowledge from 
experiments obtained with different levels of complexity and validity will 
greatly increase our understanding of the FPRs and their role in various 
inflammatory processes. 
3.2 The FPR receptors of mice and men 
There are three different members of the human FPR family whose 
expression pattern differs between leukocytes. Human neutrophils have been 
shown to express FPR and FPRL1, while monocytes in addition express also 
FPRL2 (34). The most extensively used systems for in vivo studies of 
inflammatory processes are, as mentioned above, murine models that offer 
the great asset of genetic manipulations in the murine genome. There are six 
genes with homologies to the human FPRs in the murine genome. Out of 
these six genes, only three seem to be expressed in leukocytes, namely fprl, 
fpr-rsl and fpr-rs2 (42). It is at present not known whether the expression 
% sequence identity 
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Figure 1. Structural relationships among the members of the human and murine FPR 
families. The figure depicts cross-wise comparisons of amino-acid identities between 
the FPR receptors present on human (open symbols) and murine (filled symbols) 
leukocytes. Exact amino acid (and nucleotide) identities can be found in (42). 
FPRL2 
FPRL1 
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patterns of these receptors differ between the different murine leukocytes. 
The human and murine FPRs can be subdivided by sequence relationships 
into two distinct groups (Fig. 1). The first group consists of FPR and its 
murine orthologue Fprl, whose amino acid sequences are 76% identical, 
while the second group consists of the murine Fpr-rsl and Fpr-rs2 (with a 
reciprocal amino acid identity of 81%) and the human FPRL1 and FPRL2 
(72% identity between themselves). Both Fpr-rsl and Fpr-rs2 are more 
closely related to FPRL1 than to FPRL2 (42). 
Despite the extensive use of murine models in inflammation research, few 
reports describing the activity and potency of different agonists on murine 
neutrophils have been published. It is, however, clear that the prototypic FPR 
agonist fMLF is a much less potent stimulus of murine than of human 
neutrophils (Paper IV, 115). Nonetheless, Fprl has been identified as the 
orthologue of the human FPR and has been shown to be a functional receptor 
for formylated peptides (43). Moreover, fMLF has been claimed to bind and 
activate not only Fprl, but also Fpr-rs2, although with even lower affinity 
(55). 
Our knowledge about the agonist specificities of the murine receptors is 
insufficient, but activation through these receptors seems to result in 
processes similar to those in humans, e.g., Chemotaxis (43), degranulation 
(61) and ROS production (Paper IV). Furthermore, murine and human FPR-
signaling is at least in some parts governed by the same regulatory events 
e.g., priming by LPS and homologous desensitization (Paper IV). Despite this 
similarity in regulation of chemoattractant receptor signaling, the fact that the 
neutrophils from mice and men differ not only in the relative abundance and 
receptor arsenal, but also in the ability to produce intracellular ROS, suggests 
that this particular cell type may perform partially different functions in the 
two species (Paper IV). That neutrophils are the most abundant white blood 
cell in humans, making up a total of 60-70% of the peripheral blood 
leukocytes, while being considerably less abundant in murine blood, 
contributing only approximately 10-15% (21), also implicates a different and 
perhaps less critical or different role of neutrophils in murine immunity. 
However, as opposed to this supposai it has been shown that neutrophil-
depleted mice display increased susceptibility to experimental infections with 
e.g., Staphylococcus aureus (125). 
Taken together, it is of great importance to expand our understanding of the 
murine physiology, cell function and receptor repertoire before directly 
translating results obtained in murine models of inflammation into a human 
setting. 
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3.3 FPRL1 
FPRL1 was originally cloned by screening a cDNA library from a neutrophil-
like cell line, HL-60, using the cDNA for FPR as a probe (86), and found to 
share 69% sequence identity with FPR. The sequences are particularly 
similar in the transmembrane domains and intracellular loops, suggesting that 
FPRL1 transmits the same signals as FPR, but has different agonist 
preference (130). 
3.3.1 Agonists of FPRL1 
Initially, FPRL1 was considered an orphan receptor, but was later found to 
function as a low-affinity receptor for fMLF with approximately 1000-fold 
lower affinity as compared to the FPR (34). The FPRL1 was also reported to 
function as a high-affinity receptor for the anti-inflammatory lipid mediator 
lipoxin A4 (LXA4; (39)). 
LXA4 has been found to induce calcium mobilization and Chemotaxis in 
monocytes (72, 101), but neither neutrophils nor FPRL1 transfected cells 
responded with calcium mobilization upon LXA4 stimulation (39, 114). 
LXA4 was initially discovered as an inhibitor of immune responses (reviewed 
in (104)) and has been shown to inhibit neutrophil functions (38, 68). These 
somewhat contradictory data has led to speculations of differential activation 
of second messengers in monocytes and neutrophils by LXA4, i.e., that the 
same receptor induces an inhibitory signal in neutrophils while inducing an 
activating signal in monocytes. The attempts to define specific LXA4-induced 
inhibitory signaling via FPRL1 has failed and the doubts regarding the 
correctness of the initial findings and speculations that the LXA4 effects are 
mediated, at least in part, via a receptor different from FPRL1 is getting 
stronger (24, 80, 114). 
In line with the fact that FPRL1 shares a high degree of sequence identity 
with FPR, a number of agonists seem to be shared between the two receptors 
(Table 1). The synthetic hexapeptide WKYMVm was isolated from a random 
peptide library as a potent stimulant of both monocytes and neutrophils (7, 
108). Later it was found to be an agonist for both FPR and FPRL1, with 
approximately 300 times higher affinity for the latter (27). The WKYMVm 
contains a D-methionine in its carboxy terminus and by substituting this right-
handed amino acid for its natural left-handed counterpart, generating 
WKYMVM, the receptor specificity is shifted and the resulting peptide has 
no affinity for FPR (23). Furthermore, both variants of the hexapeptide have 
affinity for FPRL2, which is the third member of the FPR family. 
By the use of transfected HEK 293 cells, the acute phase protein serum 
amyloid A (SAA) was shown to be a specific agonist for FPRL1 (114), 
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suggesting that its potent chemotactic activity on monocytes and neutrophils 
(6) is mediated by this receptor. Apart from SAA, being a protein of 104 
amino acids, mainly peptides shorter than 40 amino acids have been 
identified as activators of FPRL1 and as mentioned above, many of the 
peptides bind to two or three members of the FPR family, although with 
different affinities (Table I). Among these peptides, some are derived from 
the HIV-1 envelope proteins gpl20 and gp41, implicating a role for FPRs in 
HIV infection (66). However, no experimental evidence describing a direct 
interaction of any FPR receptor with HIV-1 envelope proteins has been 
published. Furthermore, two amyloidogenic peptide fragments, the 20 amino 
acid long PrP106-126 derived from the human prion (67) and the 42 amino 
acid form of amyloid ß (Aß42) (65), have been shown to activate FPRL1, 
indicating a possible involvement of FPRL1 in neurodegenerative diseases. 
Two FPRL1 agonists of particular interest are the C-terminal cleavage 
fragment of the human cathelicidin, LL-37 (28), and the N-terminal part of a 
ribosomal protein from Helicobacter pylori, Hp(2-20) (Paper II), which are 
both cecropin-like a-helical antimicrobial peptides (49, 96). LL-37 is the 37 
amino acid antimicrobial peptide cleaved off from human cationic 
antimicrobial protein (hCAP18) that is the only identified human cathelicidin. 
Epithelial cells have been shown to produce hCAP18, but the protein is also 
found in the specific granules of neutrophils (28). The cleavage of hC API 8 
into LL-37 is mediated by proteinase-3 (found mainly in the azurophil 
granules of neutrophils) and appears to be a strictly extracellular event, as no 
cleavage could be observed in phagolysosomes of neutrophils (111). This 
seems to indicate that the main function of LL-37 is not the killing of a 
phagocytosed prey, but is instead executed extracellularly. Hence, in addition 
to its bactericidal effect, LL-37 may function as a chemoattractant by ligation 
of FPRL1 and thereby recruit phagocytes to a site of infection in a positive 
feedback manner. The peptide thus displays an intriguing functional dualism 
in that it is both proinflammatory and directly bactericidal. 
A similar functional dualism is displayed by the H. pylori-derived Hp(2-20). 
This 19-residue peptide has a potent antibacterial effect against a broad range 
of microorganisms, although not against H. pylori itself and it has therefore 
been suggested to act on competing bacterial species present in the gut (97). 
Apart from these intriguing findings, we have shown that Hp(2-20) is also a 
complete neutrophil activator in that it is chemotactic, induces degranulation 
and activates the NADPH-oxidase to release ROS (Paper II). These effects 
are mediated by FPRL1 in neutrophils (Paper II) and with all probability 
through both FPRL1 and FPRL2 in monocytes (11). 
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Table I. Agonists for FPRL1 
Agonist Origin Alternative FPR 
preference 
References 
WKYMVm peptide library FPR, FPRL2 (23, 27) 
WKYMVM peptide library FPRL2 (23) 
fMLF1 bacteria FPR (34) 
Hp(2-20) H. pylori FPRL2 (Paper II, 11) 
LL-37 neutrophils, 
endothelial cells 
(28) 
SAA acute phase protein (114) 
Aß42 amyloid ß FPR (65) 
PrP106-126 prion protein (67) 
mitochondrial 
peptide 
N36 
mitochondrial 
peptide 
HIV-1, gp 41 
(22) 
(64) 
T21/DP107 HIV-1, gp 41 FPR (113) 
F-peptide HIV-1, gp 120 (30) 
V3-peptide HIV-1, gp 120 (109) 
MMK-1 peptide library (57) 
LXA4 lipid metabolite ?2 (39, 80) 
uPAR plasminogen 
activator receptor 
(99) 
'All agonists in the table have a preference for FPRL1, except for fMLF that exhibits 
higher affinity for FPR. 
2Receptor identity unknown, although probably no FPR (see text and (80) for details). 
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In addition to the examples given above, FPRL1 has been shown to have 
affinity for a number of other peptides (Table I). Neither of the agonists 
shows any reciprocal sequence homologies and are thus seemingly unrelated, 
supporting the notion of FPRL1 as a promiscuous receptor. 
3.3.2 Signal transduction induced by FPRL1 
Binding of a chemoattractant to its neutrophil receptor induces a number of 
cellular responses in a hierarchical manner, regulated by the concentration of 
the chemotactic factor. A directed migration is mediated by low 
concentrations of agonist and an increase in concentration results in partial 
degranulation with a concomitant alteration of the plasma membrane 
constitution. Higher concentrations of chemoattractant have the potential of 
activating the neutrophil's cytotoxic and antimicrobial responses, including 
ROS production and further degranulation. The signal transduction events of 
chemoattractant-induced cellular activation have been quite extensively 
investigated (121) and seem to involve numerous parallel pathways that with 
regard to the exact casual connections remain to be elucidated. Certain 
chemoattractants induce only a subset of cellular effector functions while 
others trigger the complete set and whether this is due to the fact that the 
various functional cellular responses are triggered by distinct signal 
transduction events (differentially induced by different chemoattractants), is 
also a matter of speculation. 
It should be pointed out that the knowledge about FPR signaling far exceeds 
what is known about the signal transduction pathways employed by FPRL1. 
Based on the similarities of the two receptors, both regarding biological 
functions, sequence homologies, and sensitivity to pertussis toxin (Paper II) 
and other pharmacological modulators, it is reasonable to believe that many 
of the signaling characteristics of FPR holds true also for FPRL1 (130). 
The binding of an agonist to a seven-transmembrane spanning GPCR leads to 
a dissociation of heterotrimeric G-proteins in the plasma membrane into a 
and ßy subunits, resulting in activation of phosphoinositide 3-kinase (PI3K) 
and phospholipase C (PLC). The FPR has been shown to be functionally 
coupled to inhibitory G-proteins (45, 62, 124) and as a consequence, FPR 
mediated responses can be specifically inhibited by pertussis toxin. The 
membrane phosphatidylinositol 4, 5-bisphosphate (PIP2) is converted by PLC 
into the secondary messengers diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3). The lipid DAG can activate members of the protein 
kinase C (PKC) family, a process in which DAG synergizes with cytosolic 
Ca2+. Cytosolic Ca2+ levels are in turn elevated as a consequence of the 
second messenger IP3, which promotes a release of Ca2+ from intracellular 
calcium stores (63). Clearly, the activation of PKC and the elevation of 
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cytosolic Ca2+ levels are key events in FPR signaling, although other events 
are probably also of importance, such as the P1P2 conversion into 
phosphatidylinositol 3, 4, 5-trisphosphate (PIP3) by the PI3K. That these and 
consecutive signaling steps are related to the cellular processes governed by 
the FPR has been established (56), although the details about how this is 
mediated remains to be established. 
Despite the limited knowledge about the details of FPR LI-mediated signal 
transduction it has been shown that also FPRL1 signaling is sensitive to 
pertussis toxin and is characterized by elevated levels of cytosolic Ca2+ 
concentrations (Paper II, 23, 27). 
3.3.3 Cellular responses mediated by FPRL1 
Many of the known FPRL1 agonists (Table 1) have been identified by 
exogenous expression of FPRL1 in various cell lines and using elevation of 
cytosolic Ca concentrations as a means of monitoring signaling activity. In 
some cases the identified FPRL1 agonists have been studied in the context of 
endogenously expressed FPRL1 on neutrophils and monocytes and in 
general, these agonists have been shown to mediate the same leukocyte 
effector functions as discussed above. In short, different FPRL1 agonists 
have been shown to mediate Chemotaxis of neutrophils and monocytes (Paper 
II, 11, 23, 27, 28, 114), granule mobilization in neutrophils (Paper II), and 
activation of the NADPH-oxidase resulting in a release of oxygen free 
radicals from both neutrophils and monocytes (Papers, II & III, 11, 23, 27). 
3.3.4 Pathophysiological roles for FPRL1 
Localized juvenile periodontitis (LJP) is a debilitating periodontal disease 
featuring aggressive bone destruction (126) that is associated with a defect in 
the patient's host defense against numerous oral bacteria. In a recent study, 
29 out of 30 patients diagnosed with LJP were shown to carry mutations in 
the FPR gene (51), resulting in impaired Chemotaxis to formylated peptides. 
Similar findings of patients with defect allelic variants of FPRL 1, showing a 
definite role of this receptor in human pathophysiology, have not yet been 
described. However, based on the fact that activation of neutrophils via 
FPRL1 results in a massive release of ROS and other potentially tissue 
destructing substances (Paper II, 23, 27), it seems plausible that this receptor, 
or modified allelic variants, should be involved in various pathological states 
involving inflammatory components. 
One infectious disease in which FPRL ! potentially is involved is the severe 
gastric inflammation caused by the bacterium Helicobacter pylori. We have 
shown that the H. pylori-derived antibacterial peptide Hp(2-20) activates 
neutrophils via FPRL 1 (Paper II). Since H. pylori do not normally penetrate 
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Figure 2. Model of immune-regulation in the gut mucosa infected with Helicobacter pylori. 
The inflammatory response is mediated by soluble substances, e.g., formylated peptides and 
Hp(2-20) that can cross the gut epithelium and attract and activate both neutrophils and 
monocytes via members of the FPR family. The phagocyte activation results in tissue 
damage due to the release of ROS and a variety ofproteolytic enzymes. The ROS released 
upon activation may also have secondary effects in that it mediates dysfunction of 
lymphocytes normally associated with defense against gastric cancer, i.e., NK cells and T 
cells (see text for details). 
into the sub-epithelial lamina propria, the direct bacteria-induced 
inflammation is likely to be dependent on soluble factors (3, 74, 105), such as 
Hp(2-20), that can cross the epithelial layer and form a chemotactic gradient 
to attract inflammatory cells. It has been speculated that an inflammatory 
response with concomitant tissue damage would be beneficial for H. pylori, 
by promoting a release of nutrients from the epithelial lining enabling 
continued bacterial growth and persistence in the mucosal tissue (13). 
Furthermore, the ROS generated upon FPRL1 activation can also have more 
specific pathophysiological effects apart from the tissue destruction 
accompanying the inflammation. We have shown that Hp(2-20) is also a 
monocyte chemoattractant and activates these cells to produce ROS that have 
secondary effects on other immune cells (Fig. 2, (11)). More specifically, the 
Hp(2-20)-induced ROS functionally inhibits lymphocytes that normally are 
associated with defense against gastric cancer, i.e., NK cells and T cells, and 
also triggers apoptosis in these cells. Based on these findings we have 
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suggested that Hp(2-20), and consequently FPRL1 (and possibly also 
FPRL2), not only contributes to the accumulation and activation of 
neutrophils and monocytes in chronic gastritis, but also that the ROS released 
from the activated phagocytes may be of relevance to the increased cancer 
risk in H. pylori infected gastric tissue due to its inhibitory effects on NK and 
T cells (Fig. 2). 
The study discussed above points to the value of increasing the complexity of 
an in vitro system. By using a mixture of cells aimed at mimicking the 
mononuclear cell infiltrate of a H. pylori infected gastric tissue (1), we were 
able to establish indirect effects of a FPRL1 agonist on cell types that in 
themselves do not respond to the agonist. It should be noted that this concept 
of indirect regulatory effects is in no way unique to FPRL1 and its agonists, 
but is in theory valid for all kinds of receptor/agonist pairs capable of 
evoking a high enough level of ROS release, e.g., fMLF/FPR (84). 
Other pathological states where FPRL1 has been postulated to play a role 
include the neurodegenerative disorders Alzheimer's disease (AD) and prion 
diseases (known as Creutzfeldt-Jakob disease, scrapie or bovine spongiform 
encephalopathy, depending on affected species). Both types of disorders are 
characterized by the formation of plaques in the brain constituting an 
inflammatory site with complex cellular reaction (100, 122). Present in the 
plaques are activated microglial cells, the brain equivalent of monocytes, 
which are believed to be the direct mediators of the inflammatory state seen 
in AD. These microglial cells express FPRL1 and amyloidogenic protein 
fragments such as the 42 amino acid form of amyloid ß (Aß42) and a peptide 
derived from the human prion protein (PrP106-126), have been shown to 
activate microglial cells via FPRL1 (65, 67, 127). 
3.4 Regulation of FPRL1 
3.4.1. Subcellular localization -exposure through granule mobilization 
Neutrophils have very little, if any, de novo protein synthesis and instead rely 
upon storing preformed molecules (including chemoattractant receptors) in 
intracellular granules for their function. The regulated exocytosis of the 
different granules ascertains upregulation of the receptors to the cell surface 
in a controlled manner (15). We have shown that FPRL1 is localized in 
different mobilizable subcellular compartments in the resting neutrophil 
(Paper III). It is a well-known fact that the neutrophil responses to 
chemoattractants can be enhanced by prior exposure to various inflammatory 
mediators, a process known as priming. This issue has been extensively 
studied, in particular regarding the production of ROS in response to 
chemoattractants, where priming agents can make cells hyper-responsive to 
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chemoattractant stimulation without activating the NADPH-oxidase per se. 
Examples of priming agents are proinflammatory cytokines such as TNF-a 
and microbial-derived substances such as LPS. There are numerous 
hypotheses regarding the mechanism underlying the priming phenomenon, 
e.g., alterations of intracellular signaling pathways (increased protein 
phosphorylation, phospholipase activity, intracellular Ca2+ changes and cross 
talk between Ca2+ increase and tyrosine phosphorylation), altered assembly of 
the NADPH-oxidase, and proteolytic processing of cell surface proteins (29, 
50, 52, 116, 119, 123). One important aspect of priming has been proposed to 
be granule mobilization with a concomitant increase in cell surface 
expression of receptors (4, 59). In the case of FPRL1 we have shown that 
LPS treatment mobilizes the secretory vesicles and gelatinase granules 
(organelles that harbor FPRL1), leading to increased levels of the receptor in 
the plasma membrane (Paper III). Furthermore, we showed that cytoplasts, 
consisting of an organelle-free cytoplasm (thus devoid of granules) 
surrounded by plasma membrane (102), could not be primed by LPS, 
indicating that receptor upregulation through granule mobilization is an 
important feature of LPS-mediated priming. 
The primed state accomplished in vitro by e.g., incubation with LPS 
corresponds to the primed state of neutrophils having extravasated in vivo 
with regards to functional modifications such as granule mobilization and L-
selectin cleavage (40). Exudated neutrophils have also been shown to display 
an increased responsiveness to both fMLF and the lactose-binding lectin 
galectin-3 as compared to peripheral blood cells, implying that priming via 
granule mobilization is an important process also in vivo (59). 
The degranulation observed in in vivo migrated neutrophils resembles that of 
cells primed in vitro in that a strict hierarchical order of degranulation 
between the different granule types is employed. As mentioned above, also 
low doses of chemoattractants promote granule mobilization (Paper II) and 
therefore these substances may prime neutrophils to subsequent 
chemoattractant-induced activation. However, mechanisms also exist to 
avoid a continuous positive feedback-regulated priming/activation of 
neutrophils. 
3.4.2. Desensitization - termination of signaling capacity 
When neutrophils have been activated by a chemoattractant they rapidly 
become refractory to further or subsequent stimulation with the same agonist 
or another agonist using the same receptor (Papers II & IV). This 
phenomenon, called homologous desensitization, has been described not only 
for chemoattractant receptors such as FPR, FPRL1, PAFR, C5aR, IL8R 
(120), but also for other GPCRs such as the rhodopsin (70) and ß-adrenergic 
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receptors (31). For many GPCRs, homologous desensitization has been 
implicated as an important physiological feedback mechanism that protects 
against acute and chronic receptor over stimulation (37) and in all probability 
this is the case also for the chemoattractant receptors. 
Upon ligand stimulation of chemoattractant receptors the signal is terminated 
by uncoupling the receptor from the G-protein as a result of receptor 
phosphorylation. This uncoupling is probably the cause for the 
desensitization, together with internalization of the ligated receptor. A family 
of GPCR kinases mediates the initial phosphorylation of the carboxyl 
terminus of the receptor. After phosphorylation, arrestins bind to the 
receptors and sterically prevents binding and activation of the G-protein. 
Arrestins are a group of adaptor proteins whose first member was identified 
in the retina as an inactivator of light-activated rods (91). The binding of 
arrestins also targets most GPCRs to clathrin-coated vesicles for 
internalization (37). Prossnitz and co-workers have, however, recently shown 
that the internalization of chemoattractant receptors, such as FPR and C5a, 
occurs independently of both arrestin and clathrin (46, 73), indicating that 
these receptors are internalized through alternative pathways. Nonetheless, 
the carboxy-terminal phosphorylation is a key event in both the 
desensitization and agonist-induced uptake of FPR. This was shown in 
experiments using cells expressing a mutated FPR that lacked the potential 
carboxy-terminal phosphorylation sites. These cells showed normal migration 
to fMLF, but were defect in both desensitization and fMLF-induced 
internalization (55, 93). With regards to FPRL1, the exact mechanisms 
underlying desensitization and internalization are yet to be established. The 
receptor, however, exhibits similar homologous desensitization on a 
functional level as FPR (Paper II, 11, 23). 
In addition to homologous desensitization, a number of studies describe a 
phenomenon called heterologous desensitization or cross-desensitization, 
where the activation of a certain chemoattractant receptor results in 
inactivation also of receptors not occupied by agonists (2). This effect is 
supposedly the result of phosphorylation of un-liganded receptors by various 
second messenger-activated kinases, but may also be influenced by other 
signaling events downstream of the G-protein (2, 66, 120). Although more 
work is needed in order to elucidate the precise mechanisms behind cross-
desensitization it seems clear that different chemoattractant receptors can 
affect each other at several different levels. 
As mentioned in Paper I, yet another form of desensitization or 
downregulation of FPRL1 responses may exist. We have found that 
stimulation of neutrophils with the H. pylori neutrophil activating protein 
(Hp-NAP, (105)) makes the cells unable to respond to the FPRL1 agonist 
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Hp(2-20). The fact that the Hp-NAP-stimulated cells still respond normally 
to other FPRL1 agonists (Bylund, unpublished data) implicates the existence 
of a novel ligand-specific, as contrasted to the established receptor-specific, 
desensitization process. Although the mechanism behind this interesting 
interaction is yet to be determined, this finding suggest that receptor 
desensitization is not the only way of downregulating signaling through 
FPRL1. 
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4. The FPR family - a receptor family for 
pattern recognition? 
The main distinction between the adaptive and the innate immune defenses 
lies in the repertoire of protective mechanisms and receptors used for 
immune recognition. The T and B cells of the adaptive immune system rely 
on receptors that are not encoded in the germ-line or predestined to recognize 
particular antigens. Instead, a large arsenal of receptors are generated at 
random and then selected for clonal expansion upon recognition of the 
antigen for which they, by chance, are specific. This complex system ensures 
the generation of lymphocytes bearing high affinity receptors for practically 
any imaginable antigen. Regardless of how useful such receptors may be, it 
takes time to expand the specific cell clones, and the structural information 
cannot be passed on to coming generations but each new generation has to go 
through the same procedure. In contrast, the innate immune system relies on 
germ-line encoded receptors with predetermined specificities. A drawback in 
this approach is that the human genome not possibly could harbor specific 
receptors for the wide range of microorganisms encountered during a life 
span. Furthermore, the much shorter generation time and higher mutation 
frequency of the microorganisms would undoubtedly lead to humans being 
"outsmarted" by the microbes before long. Therefore, the innate immune 
system has adopted a strategy to recognize a few, highly conserved, antigens 
present on a large group of microorganisms by so-called pattern recognition 
receptors (83). 
Some of the most studied examples of pathogen-associated molecular 
patterns (PAMPs) recognized by pattern recognition receptors are LPS, 
mannans, bacterial flagellin, peptidoglycan, unmethylated bacterial DNA 
sequences, double stranded RNA and lipoteichoic acids, representing clearly 
non-self antigens shared by, and essential for, large groups of microbes. In 
higher organisms, pattern recognition receptors are usually present on a wide 
array of cell types, not least on antigen presenting cells, and the activation of 
these receptors serves to mobilize the combined forces of the adaptive and 
innate immunity in order to combat the infection. Many of the PAMPs are 
recognized by a class of pattern recognition receptors known as Toll-like 
receptors (TLRs), present in organisms as diverse as insects and mammals 
(81). The TLRs are not 7-transmembrane spanning receptors signaling via G-
protein activation, instead the signal transduction utilizes a number of 
different adaptor proteins and kinases (82). Ultimately, TLR activation leads 
to the release of NF-KB that gains access to the nucleus and functions as a 
transcriptional activator of a number of inflammatory- and immune response 
genes (118). Human neutrophils have been shown to express at least three 
TLRs, namely TLR1, -2 and -4. These receptors have been implicated in 
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responses to e.g., peptidoglycans/lipoteichoic acids and LPS by other cells 
(53), although direct evidence of their role in mediating neutrophil responses 
are currently lacking. 
Although not traditionally regarded as a pattern recognition receptor, the 
chemoattractant receptor FPR can in a way be classified as such. Formylation 
of newly synthesized proteins is a unique signature of bacterial metabolism 
and thus, the presence of formylated peptides would serve as a highly 
relevant PAMP, being both non-self and essential for bacterial metabolism. 
The importance of proper recognition of formylated peptides have been 
described in a murine model where mice lacking Fprl were clearly more 
susceptible to bacterial infections than wild ty pe mice (43). Another 
interesting notion in this context is that also mitochondria produce formylated 
peptides, a reminder of their bacterial heritage. These peptides are 
presumably released upon tissue damage and may thus contribute to the 
proinflammatory signal accompanying such an event (94). 
If FPR can be regarded as a pattern recognition receptor, is this also the case 
for FPRL1? The recruitment of neutrophils is desirable not only in case of 
infection, but also during the inflammatory event accompanying tissue 
damage caused by mechanical injury or trauma. In the event of injury cells 
are damaged, promoting a leakage of endogenous molecules not normally 
present in the extracellular space. Accompanying the destruction of cells, a 
plethora of proteases and other hydrolytic enzymes are activated. For 
example, upon epithelial damage, the constant equilibrium involved in blood 
coagulation is affected, including very complex proteolytic cascades such as 
the thrombin-generating pathway and the fibrinolytic system (18). These 
events may lead to the generation of peptide fragments not normally present 
extracellularly which could function as a danger signal to alert the innate 
immune system. It is interesting to note that many of the known activators of 
FPRL1 represent cleavage products of full-length proteins that in themselves 
lack affinity for the receptor (e.g., Aß42, PrP106-126, LL-37, mitochondrial 
peptide). Recently, a direct link between the fibrinolytic machinery and the 
inflammatory response was demonstrated and a naturally occurring cleaved 
form of the urokinase-type plasminogen activator receptor (uPAR) was 
shown to induce Chemotaxis in FPRLl-transfected cells (99). Thus, the 
pattern recognized by FPRL1 may not be pathogen-associated, but rather 
FPRL1 can be said to be a sensor of (endogenous) danger signals constituted 
by different proteolytic cascades. This type of recognition bears resemblance 
with the prototypic pattern recognition receptor in Drosophila, Toll, which is 
not activated directly by any known PAMP, but instead recognizes the 
proteolytically cleaved form of the endogenous protein Spaetzle. Normally, 
the full-length Spaetzle is not recognized by Toll but upon cleavage of the 
protein in response to the proteolytic cascade (which in itself is a host 
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defense event triggered by e.g., bacterial infection), the resulting carboxy-
terminal fragment activates the receptor. In this context Toll is not really a 
pattern recognition receptor but rather a sensor of the danger signal 
constituted by the proteolytic cascade (58). 
The presence of a neutrophil receptor capable of recognizing a danger signal 
composed of partially degraded peptides would contribute to the infiltration 
of neutrophils that can dispose of cellular debris resulting from the initial 
injury. An exception to the hypothesis that FPRL1 recognizes proteolytically 
processed peptide fragments is SAA. This acute phase protein does not 
require proteolytic cleavage to gain affinity for FPRL1 but on the other hand 
SAA is generated predominately in association with inflammation and/or 
tissue injury (76). Furthermore, hCAP18 is processed into the FPRL1 ligand 
LL-37 as a result of neutrophil activation (111) and could thus serve to 
sustain inflammation in a positive feedback manner in a similar way as SAA. 
Regarding the microbial-derived agonists ofFPRLl i.e., the HIV-1 derived 
peptides and Hp(2-20), they could possibly represent microbial strategies to 
hijack the innate immune system, in the case of H. pylori in order to promote 
the release of nutrients following inflammatory damage of the gut epithelium 
(13). 
Clearly, not just any cleaved peptide can function as an FPRL1 agonist and 
much more work has to be done in order to elucidate the specific structural 
requirements of peptide fragments capable of activating FPRL1, i.e., the 
actual structure of the recognized pattern. The different FPRL1 agonists do 
not show any similarities on the sequence level, giving rise to the notion of a 
promiscuous receptor. On the other hand, agonists may well show similarities 
on higher levels, e.g., in the physico-chemical properties of the correctly 
folded peptide. In this context it is interesting to note that LL-37 and Hp(2-
20) both adopt a positively charged, amphipathic, a-helical structure, which 
is usually the minimal requirement for cecropin-like peptides to exert 
antibacterial effects (36). The antibacterial effect of cecropin-like peptides is 
probably dependent on non-specific interactions with bacterial membranes 
and is thus quite different from the specific interaction with FPRL1 displayed 
by Hp(2-20) and LL-37. However, these two peptides clearly have structural 
features in common. Cecropin-like antibacterial peptides in general do not 
activate neutrophils and while the ability to form a positively charged a-helix 
is necessary to exert any bactericidal effect it is not a sufficient criterion to 
activate FPRL1 (Bylund, unpublished data). 
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5. Concluding remarks 
During the last decade an impressive amount of knowledge has been gained 
about the FPR family in terms of structures, expression patterns, signaling 
processes, biological roles and regulation of its signaling. The majority of 
what is known today would have been impossible to address before the genes 
encoding the different receptors were cloned and exogenous expression 
possible. A lot more information can be found on the FPR as compared with 
its two homologues FPRL1 and FPRL2, which is probably due to the 
existence of a prototypic agonist (fMLF) for this receptor. It is interesting to 
note that FPRL1 has switched from being an orphan receptor to being 
considered a promiscuous receptor, with numerous described ligands. This 
has been a process of just a few years and simultaneously FPRL1 has 
switched positions from a FPR homologue to being an important receptor in 
its own right. While research on FPR continues, the development of selective 
high-affinity agonists (and antagonists) for FPRL1 will undoubtedly generate 
large amounts of interesting data in the future and possibly uncover unique 
features of this receptor. Hopefully, future research will also reveal whether 
FPRL1 should still be considered a promiscuous receptor with affinity for a 
number of unrelated agonists, or if the apparently unrelated agonists turn out 
to share a common pattern on a higher level than the sequence level. This 
common pattern may well be on a physico-chemical level of the folded 
peptide/protein or could be of a more subtle nature where FPRL1 could be 
considered a pattern recognition receptor or sensor of danger signals. Similar 
to FPRL1, an expansion in knowledge may be expected for the third FPR 
variant, FPRL2, in coming years. Hitherto, we have shown that FPRL2 is a 
functional monocyte receptor for various FPRL1 agonists (11, 23), although 
no specific, high-affinity FPRL2 agonists have yet been described. In all 
probability, increased understanding of FPRL2 as an important receptor in its 
own right may help to complete the picture and bring about a more precise 
understanding of the FPR family and its role in inflammatory processes. 
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Populärvetenskaplig sammanfattning på svenska i form av 
E-mailkorrespondens mellan författaren och hans 
humanistiskt skolade faster 
Original Message  
From: Barbro Bylund <BARBRO@nola.ornskoldsvik.se> 
To: <iohan.bvlund@microbio.gu.se> 
Sent: Tuesday, February 05, 2002 10:55 AM 
Hej för åttonde gången! 
Nu krånglar min dator eller jag alldeles förskräckligt. 
Jag skulle bara maila och fråga efter dels den exakta titeln på din blivande avhandling dels 
några meningar på vanlig svenska, som talar om vad du sysslar med om det nu går att 
förklara. Kanske på den nivån att en natuvetargymnasist skulle få ett hum. 
Flälsningar från Fastern 
From: "Johan Bylund" <iohan.bvlund@,microbio.gu.se> 
To: "Barbro Bylund" <BARBRO@nola.ornskoldsvik,se> 
Subject: Re: 
Date sent: Tue, 5 Feb 2002 11:25:31 +0100 
Hoppla, det blir inte helt lätt. Ok, arbetsnamnet är "Pattern recognition by formyl peptide 
receptors in neutrophils" Den handlar om HUR vita blodkroppar (neutrofiler) känner att de 
behövs och "luktar" sig fram till det område i kroppen som behöver dem. Detta är mycket 
bildligt talat, ett konkret exempel -man skär sig i fingret (vilket innebär att det kommer in 
en massa bakterier) och väldigt fort blir det rött, svullet, ömt osv. dvs. det blir 
inflammation. Inflammation är helt enkelt en ansamling och aktivering av neutrofiler (en 
typ av vita blodkroppar) som på nåt sätt känner av att det finns bakterier i såret och 
skyndar sig dit. Är du med? 
De molekyler som känner av att bakterier finns i såret sitter på ytan av de vita 
blodkropparna och kallas receptorer (ännu ett ord i titeln -du ser vi betar av dem!). Dessa 
receptorer liknar väldigt mycket den typ av receptorer som vi t.ex luktar med och är 
grymma på att särskilja olika molekyler (tex. luktämnen ifall det rör sig om dessa, eller 
olika molekyler som kommer ifrån bakterier i mitt fall), och min avhandling rör en 
speciell klass av receptorer som alltså sitter på neutrofilerna och medför igenkänning av 
t.ex bakterier. Vad jag har pysslat med är att kolla på hur dessa receptorer fungerar, 
regleras, signalerar och vilka cell-processer de styr, och jag lanserar en liten hypotes om 
att en specifik receptor (FPRL1 är det poetiskt högtravande namnet) som tidigare trots 
vara promiskuös (japp, det är uttrycket som används för att indikera att receptorn kan 
känna igen en massa olika molekyler utan några likheter sinsemellan), i själva verket kan 
sägas reagera på en sorts "varningssignaler" i form av sönderbrutna molekyler som bildas i 
samband med vävnadsskada. Igenkänning av varningssignaler = pattern recognition. 
Har jag tappat dig fullständigt?? Hursom, dessutom har jag gjort ett litet knäck av att kolla 
hur vissa cell-funktioner (som styrs av dessa receptorer) fungerar i möss, och eftersom det 
är en hel del skillnader mot hur det står till i människa (på vårt labb jobbar vi normalt med 
mänskliga blodceller som vi tar ifrån blodgivarblod) och då möss används så rackarns 
mycket i olika typer av inflammationsforskning och resultaten översätts ofta rakt av till 
människan, försöker vi tala om att det inte är så enkelt utan att neutrofiler skiljer sig rätt 
mycket åt i Möss och Människor (japp, jag funderar på att referera till Steinbeck). Sen 
hängerjag in en direkt jämförelse av hur den klass av receptorer jag jobbar med skiljer sig 
mellan de olika arterna. För att popularisera tillställningen så diskuterar jag oxå direkta 
sjukdomstillstånd då "mina" receptorer med största sannolikhet spelar en viktigt roll t.ex, 
magsår, reumatism, alzheimers mfl. 
Huga, det är riktigt svårt att förklara populärvetenskapligt vad tusan man pysslar med, är 
det nåt som verkar helt obegripligt så får du säga till. 
Hoppas allt är lysande! /johan 
From: Barbro Bylund <BARBRO@nola.ornskoldsvik.se> 
To: <iohan.bvlund@,microbio.gu.se> 
Sent: Wednesday, February 06, 2002 10:25 AM 
Johan, vad intressant och skojigt du berättar om din forskning. Jag fattade det mesta efter 
ett par långsamma läsningar. Den där sammanfattningen tycker jag du ska skicka till flera. 
Det jag undrar över är om dina laborationer stöder tesen att FPRL1 reagerar på de där 
varningssignalerna. Är det kanske lika viktigt ur forskningssynpunkt att upptäcka att så 
inte är fallet? 
Du behöver inte snällt svara på stubben men någon gång när du har tid. / Babbi 
From: "Johan Bylund" <iohan.bvlund@,microbio.gu.se> 
To: "Barbro Bylund" <BARBRO@,nola.ornskoldsvik.se> 
Subject: Re: 
Date sent: Wed, 6 Feb 2002 20:25:31 
Njae både och. Mina arbeten som jag baserar avhandlingen på handlar om 
1) Interferens mellan olika substanser som aktiverar cellerna genom bla. FPRL1 
2) Identifiering av en helt ny aktivator av FPRL1 (substansen kommer ifrån bakterien som 
orsakar magsår och kan därför hjälpa till att förklara den elakartade inflammationen som 
finns vid magsår) 
3) Reglering av FPRL1 -det är känt sen förr att om de vita blodkropparna först stimuleras 
med vissa faktorer så kan aktiviteten som medieras via FPRL1-liknande receptorer öka 
rätt dramatiskt. Vi har visat att denna ökning beror på att FPRL1 lagras i små bubblor inuti 
cellen och dessa bubblor släpps lösa vid stimulering av cellen --> fler FPRL1 molekyler 
på cellen = högre effekt vid stimulering 
4) Karaktärisering av FPRL1 liknande receptorer hos möss, och specifikt fokuserat på en 
av de cellulära effekter som dessa receptorer styr (bildningen av fria syreradikaler). 
För att sy ihop detta så skriver jag avhandlingen som en översiktsartikel (tänkt att 
publiceras i sig) över denna typ av receptorer. Vinklingen mot varningssignaler bygger jag 
dels på andra arbeten jag gjort (som undersöker specificiteten hos FPRL1 map. hur 
aktivatorn ser ut) samt en massa andra publicerade artiklar. Jag försöker sammanfatta 
fåltet så att säga. Det finns såklart alltid undantag som bekräftar regeln, så visst finns det 
fall där min hypotes inte riktigt går i hamn, men fokuseringen på "pattern recognition" är 
rätt spekulativ och inte alls bevisad. 
Har förresten fatt mkt snygga resultat idag (toppen) men oxå fått en artikel refuserad av 
folk som vägrar förstå sig på geniala experiment ;) (botten). Upp och ner hela tiden alltså! 
Ha det fint! /j 
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På grund av upphovsrättsliga skäl kan vissa ingående delarbeten ej publiceras här. 
För en fullständig lista av ingående delarbeten, se avhandlingens början.
Due to copyright law limitations, certain papers may not be published here.
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